In an interview with Law360 about the US Food and Drug Association's recent guidance on biosimilars, Morgan Lewis partner Christopher Betti noted that, "With this final guidance, I think we are closer to seeing the first interchangeable product out there." He added, "Biosimilars have been waiting for this particular clarity before moving down a path to show interchangeability."